Acitretin - Allergan

Drug Profile

Acitretin - Allergan

Alternative Names: Acitretine; Etretin; Neotigason; RO 101670; Soriatane

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Allergan; Aralez Pharmaceuticals Inc.; Innovaderm Research; Roche; Stiefel Laboratories; University of Medicine & Dentistry of New Jersey
  • Class Antipsoriatics; Keratolytics; Retinoids
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriasis
  • Discontinued Cancer; Dermatitis

Most Recent Events

  • 10 Jul 2017 Discontinued - Phase-II for Psoriasis (Adjunctive treatment) in USA (PO), because not listed on Allergan pipeline, July 2017
  • 10 Jul 2017 Discontinued - Phase-II/III for Dermatitis in Canada (PO), because not listed on Allergan pipeline, July 2017
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top